13F-HR filed by B Group, Inc.
B Group, Inc. filed this 13F-HR for the quarter ended 2026-06-30, filed 2026-08-14, with 19 holding rows worth $213,008,589.
- Accession
- 0001420506-26-001657
- Filer
- CIK 2043476
- Filed
- 2026-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2026
A holdings report, 19 entries on the cover page, a total value of $213,008,589 stated on the cover page (in dollars after the unit check, H1), rows summing to $213,008,589 with VALUE read as dollars as filed, 13F file number 028-25141. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| INVESCO QQQ TR | 46090E953 | PUT | 50,000 | $36,820,000 | dollars as filed | put |
| ADMA BIOLOGICS INC | 000899104 | COM | 3,262,542 | $27,307,477 | dollars as filed | |
| PALISADE BIO INC | 696389402 | COMMON STOCK | 11,414,285 | $23,855,856 | dollars as filed | |
| NRX PHARMACEUTICALS INC | 629444209 | COM NEW | 4,091,767 | $16,735,327 | dollars as filed | |
| FAETH THERAPEUTICS INC | 81728A207 | COM NEW | 610,169 | $15,254,225 | dollars as filed | |
| TAYSHA GENE THERAPIES INC | 877619106 | COMMON STOCK | 1,800,556 | $12,261,786 | dollars as filed | |
| PRAXIS PRECISION MEDICINES I | 74006W207 | COM NEW | 33,237 | $11,127,415 | dollars as filed | |
| CELLECTIS ADS | 15117K103 | COM | 3,281,501 | $9,844,503 | dollars as filed | |
| ZAI LAB LTD ADR | 98887Q104 | ADR | 450,646 | $8,562,274 | dollars as filed | |
| STRUCTURE THERAPEUTICS INC COMP | 86366E106 | EQUITY | 140,000 | $7,513,800 | dollars as filed | |
| ORUKA THERAPEUTICS INC COM | 687604108 | Stock | 75,000 | $7,137,750 | dollars as filed | |
| IOVANCE BIOTHERAPEUTICS INC | 462260100 | COM | 1,500,000 | $6,240,000 | dollars as filed | |
| SPYRE THERAPEUTICS INC | 00773J202 | COM NEW | 70,000 | $6,214,600 | dollars as filed | |
| AURA BIOSCIENCES INC | 05153U107 | COMMON STOCK | 764,243 | $5,426,125 | dollars as filed | |
| ASSEMBLY BIOSCIENCES INC | 045396207 | COMMON STOCK | 175,706 | $4,828,401 | dollars as filed | |
| BRIGHT MINDS BIOSCIENCES INC | 10919W405 | COMMON STOCK | 67,500 | $4,738,500 | dollars as filed | |
| ULTRAGENYX PHARMACEUTICAL IN | 90400D108 | COM | 135,000 | $4,507,650 | dollars as filed | |
| SIGHT SCIENCES INC | 82657M105 | COMMON STOCK | 970,000 | $3,656,900 | dollars as filed | |
| FOGHORN THERAPEUTICS INC | 344174107 | COMMON STOCK | 200,000 | $976,000 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001420506-26-001657 | this filing | 2026-08-14 | acceptance time not in the bulk data set |